Tudor Investment Corp ET AL Has $13.09 Million Stock Position in Alphatec Holdings, Inc. $ATEC

Tudor Investment Corp ET AL grew its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 608.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 900,491 shares of the medical technology company’s stock after acquiring an additional 773,367 shares during the period. Tudor Investment Corp ET AL owned about 0.61% of Alphatec worth $13,093,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Granite Investment Partners LLC increased its holdings in Alphatec by 320.6% in the second quarter. Granite Investment Partners LLC now owns 1,720,944 shares of the medical technology company’s stock valued at $19,102,000 after purchasing an additional 1,311,748 shares during the period. Assenagon Asset Management S.A. lifted its holdings in Alphatec by 7,083.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 750,429 shares of the medical technology company’s stock worth $10,911,000 after buying an additional 739,982 shares during the period. Two Sigma Investments LP lifted its holdings in Alphatec by 59.0% during the 3rd quarter. Two Sigma Investments LP now owns 1,794,324 shares of the medical technology company’s stock worth $26,089,000 after buying an additional 665,634 shares during the period. Oberweis Asset Management Inc. bought a new stake in shares of Alphatec in the 3rd quarter valued at about $6,705,000. Finally, Balyasny Asset Management L.P. grew its position in shares of Alphatec by 173.1% in the 2nd quarter. Balyasny Asset Management L.P. now owns 719,469 shares of the medical technology company’s stock valued at $7,986,000 after buying an additional 456,063 shares during the last quarter. Institutional investors and hedge funds own 66.35% of the company’s stock.

Analyst Upgrades and Downgrades

ATEC has been the subject of a number of analyst reports. Loop Capital set a $25.00 price objective on Alphatec in a research report on Wednesday, December 10th. HC Wainwright reiterated a “buy” rating and issued a $24.00 target price on shares of Alphatec in a report on Monday, January 12th. Piper Sandler reissued an “overweight” rating on shares of Alphatec in a research report on Wednesday, February 25th. TD Cowen restated a “buy” rating on shares of Alphatec in a report on Tuesday, January 27th. Finally, Stifel Nicolaus reduced their price objective on shares of Alphatec from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.82.

Alphatec Stock Down 2.8%

Shares of Alphatec stock opened at $12.37 on Friday. Alphatec Holdings, Inc. has a one year low of $8.81 and a one year high of $23.29. The company has a debt-to-equity ratio of 40.35, a current ratio of 2.06 and a quick ratio of 1.28. The stock’s 50-day moving average is $14.17 and its 200 day moving average is $16.77. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of -13.02 and a beta of 1.02.

Alphatec (NASDAQ:ATEC) last issued its earnings results on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $212.93 million during the quarter, compared to the consensus estimate of $212.67 million. During the same quarter in the previous year, the firm posted ($0.23) earnings per share. The company’s revenue for the quarter was up 20.4% compared to the same quarter last year. Equities research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insider Buying and Selling

In other Alphatec news, EVP David Sponsel sold 163,452 shares of the firm’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $12.52, for a total value of $2,046,419.04. Following the completion of the sale, the executive vice president directly owned 504,932 shares in the company, valued at approximately $6,321,748.64. This trade represents a 24.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Craig E. Hunsaker sold 82,765 shares of Alphatec stock in a transaction on Monday, March 9th. The shares were sold at an average price of $12.45, for a total transaction of $1,030,424.25. Following the completion of the sale, the executive vice president directly owned 1,726,209 shares of the company’s stock, valued at approximately $21,491,302.05. This trade represents a 4.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 826,972 shares of company stock worth $11,285,386 over the last ninety days. 20.90% of the stock is owned by company insiders.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.